We are live on ! Find out more
First Manhattan

First Manhattan Portfolio holdings

AUM $36.1B
1-Year Est. Return 11.5%
This Fund
S&P 500
This Quarter Est. Return
+1.8%
1 Year Est. Return
+11.5%
3 Year Est. Return
+74.65%
5 Year Est. Return
+103.66%
10 Year Est. Return
+354.63%
AUM
$38.1B
AUM Growth
+$224M
Cap. Flow
-$29.6M
Cap. Flow %
-0.08%
Top 10 Hldgs %
55.36%
Holding
766
New
52
Increased
218
Reduced
307
Closed
37

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$166M
2
CSL icon
Carlisle Companies
CSL
+$142M
3
CRM icon
Salesforce
CRM
+$109M
4
LB
LandBridge Co
LB
+$77.3M
5
SNPS icon
Synopsys
SNPS
+$46M

Sector Composition

Rank Sector Weight
1 Financials 42.89%
2 Technology 22.5%
3 Consumer Discretionary 7.19%
4 Communication Services 6.82%
5 Healthcare 6.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
USCB icon
701
USCB Financial Holdings
USCB
$396M
$184K ﹤0.01%
10,000
ALDX icon
702
Aldeyra Therapeutics
ALDX
$91.7M
$180K ﹤0.01%
34,745
CERS icon
703
Cerus
CERS
$587M
$169K ﹤0.01%
82,000
IMRX icon
704
Immuneering
IMRX
$279M
$160K ﹤0.01%
24,245
PAVM icon
705
PAVmed
PAVM
$33.9M
$158K ﹤0.01%
23,803
NEXT icon
706
NextDecade
NEXT
$1.85B
$156K ﹤0.01%
29,550
DNP icon
707
DNP Select Income Fund
DNP
$4.18B
$137K ﹤0.01%
+13,638
New +$137K
NCA icon
708
Nuveen California Municipal Value Fund
NCA
$299M
$122K ﹤0.01%
13,621
UG icon
709
United-Guardian
UG
$35M
$105K ﹤0.01%
17,062
NRK icon
710
Nuveen New York AMT-Free Quality Municipal Income Fund
NRK
$900M
$101K ﹤0.01%
10,010
-16,487
-62% -$167K
EEX
711
DELISTED
Emerald Holding
EEX
$97.3K ﹤0.01%
21,763
-3,575
-14% -$15.4K
MDXH icon
712
MDxHealth
MDXH
$21.1M
$96.4K ﹤0.01%
27,000
CALC icon
713
CalciMedica
CALC
$12M
$87.2K ﹤0.01%
13,226
PTEN icon
714
Patterson-UTI
PTEN
$3.87B
$85.8K ﹤0.01%
14,041
KLTR icon
715
Kaltura
KLTR
$211M
$82K ﹤0.01%
50,000
IOVA icon
716
Iovance Biotherapeutics
IOVA
$2.23B
$79.2K ﹤0.01%
28,998
-25,302
-47% -$58.5K
OGN icon
717
Organon & Co
OGN
$3.55B
$73.9K ﹤0.01%
10,301
-137
-1% -$1.08K
ABUS icon
718
Arbutus Biopharma
ABUS
$865M
$67.3K ﹤0.01%
14,000
OPK icon
719
Opko Health
OPK
$921M
$65.2K ﹤0.01%
51,750
VLN icon
720
Valens Semiconductor
VLN
$176M
$61.7K ﹤0.01%
43,458
ZVIA icon
721
Zevia
ZVIA
$108M
$51K ﹤0.01%
22,000
OVID icon
722
Ovid Therapeutics
OVID
$435M
$42.4K ﹤0.01%
26,000
ORIO
723
Orion Digital Corp
ORIO
$15.4M
$28.7K ﹤0.01%
26,400
GROV icon
724
Grove Collaborative
GROV
$45M
$12.8K ﹤0.01%
11,662
PDSB icon
725
PDS Biotechnology
PDSB
$38.1M
$11.5K ﹤0.01%
15,000

Similar funds

First Manhattan's Q4 2025 Portfolio in Review

As of Q4 2025, First Manhattan held 766 positions worth $38.1B, up 0.59% from $37.9B the previous quarter. Its ten largest holdings account for 55% of the portfolio.

First Manhattan's Q4 2025 filing shows 52 new, 218 increased, 307 reduced and 37 closed positions. Its largest new stake was Carlisle Companies: 438,491 shares worth $140M. The largest sale was Berkshire Hathaway Class A, an estimated $434M.

By sector, the portfolio is most concentrated in Financials at 43% of assets, down from 44% a quarter earlier, followed by Technology and Consumer Discretionary.

  • First Manhattan's largest Q4 2025 buy was Carlisle Companies: 438,491 shares worth $140M.
  • First Manhattan added most to Boston Scientific in Q4 2025, an estimated $166M increase.
  • First Manhattan's biggest Q4 2025 reduction was Berkshire Hathaway Class A, cutting an estimated $434M.
  • First Manhattan fully exited Nice in Q4 2025, selling an estimated $31.8M.
  • First Manhattan's ten largest holdings make up 55% of its $38.1B portfolio in Q4 2025.
  • First Manhattan opened 52 new positions and closed 37 in Q4 2025.
  • First Manhattan's portfolio value rose 0.59% quarter-over-quarter to $38.1B.

Based on First Manhattan's 13F filing for Q4 2025, filed 17 Feb 2026.